Adalvo is pleased to announce the addition of Ibrutinib 140mg, 280mg, 420mg & 560mg Film Coated Tablets to our product Portfolio.
Our product is being developed based on the reference brand IMBRUVICA and is indicated in the treatment of mantle cell lymphoma, chronic lymphocytic leukaemia and Waldenström’s macroglobulinaemia. Ibrutinib is being developed by our sister company, which forms part of the Aztiq group, having a state-of-the-art R&D and manufacturing facility, with several GMP inspections already successfully completed.
The brand sold approximately $7.34Bn globally in 2021 with Global 3Y CAGR at 10%, according to IQVIA.
With our clearly defined product pathway, we expect to launch the product on Day-1, in all major markets.